[Possibilities of neurotrophic therapy for delayed speech development]

Area of Science:

• Neuroscience
• Pediatrics
• Speech-Language Pathology

Background:

• Delayed speech development (DSD) affects numerous children.
• Understanding effective therapeutic interventions is crucial for pediatric care.
• Neurotrophic therapy presents a potential treatment avenue.

Purpose of the Study:

• To analyze the efficacy of neurotrophic therapy in children with delayed speech development.
• To evaluate treatment outcomes in cases of isolated speech disorder (ISD) and speech disorder within general psychomotor developmental delay (PDD).
• To explore the role of neurotrophic therapy, specifically cortexin, in improving speech and behavior.

Main Methods:

• A cohort of 266 children with DSD received neurotrophic therapy.
• Dynamic clinical, laboratory, functional, and neuropsychological examinations were conducted.
• Cortexin was used in monotherapy for some participants.

Main Results:

• Neurotrophic therapy demonstrated effectiveness for both ISD and speech disorders within PDD.
• A subset of children with PDD showed a lack of response, suggesting a need for individualized treatment.
• Cortexin monotherapy improved speech development, behavior, and potentially cognitive functions like self-control.

Conclusions:

• Neurotrophic therapy is an effective treatment for various forms of delayed speech development in children.
• Individualized treatment approaches, potentially incorporating non-drug methods, are important for non-responders.
• Cortexin shows promise as a safe and effective monotherapy for DSD, with additional behavioral and cognitive benefits.